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Among patients with obstructive coronary artery disease,
percutaneous coronary intervention (PCI) has become a
widely used therapy, especially among those presenting with
acute ischemic events such as myocardial infarction and
unstable angina (1). Since its introduction into clinical
practice, PCI has had two Achilles’ heels: early thrombosis
and delayed restenosis, leading to the need for repeat
procedures. Advances in antithrombotic therapy have low-
ered the risk of acute thrombosis and the associated isch-
emic complications of death and myocardial infarction (2).
Coronary stenting has had a major impact on our ability to
successfully treat the acute problem of plaque dissection and
abrupt closure and markedly reduce late restenosis and the
need for repeat revascularization procedures (3).
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As the procedure has moved from one largely involving
balloon angioplasty to one centered around stenting, first
with bare-metal stents (BMS) and now with drug-eluting
stents (DES), the distribution of procedural complications
also has changed, especially regarding the timing of risk. In
the era of balloon angioplasty, abrupt closure was mainly
concentrated in the first 24 h after the procedure. If patients
survived that very early period without an ischemic compli-
cation, then there was a gradually increasing risk of reste-
nosis over approximately the next 6 months. Advances in
antithrombotic therapy lowered the risk of abrupt closure,
and the risk of restenosis with subsequent repeat revascu-
larizations was dramatically lowered with the increasing use
of stents. However, simultaneously, subacute stent throm-
bosis emerged as a new, dramatic clinical problem with
severe clinical consequences (4). Fortunately, treatment with
dual antiplatelet therapy with the combination of aspirin
and a thienopyridine was found in randomized clinical trials
to reduce this risk substantially (5). Observational studies
then suggested that this combination of drugs was needed
for 2 to 4 weeks after the procedure because there seemed to
be an early clustering of risk and ischemic events attributable
to subacute stent thrombosis (6).
Because the putative mechanism of benefit of DES would
be less neointimal proliferation within the stented segment
compared with that induced by BMS, it was acknowledged
that implantation of a DES might require antiplatelet
therapy beyond the 1-month period standard for BMS. The
key trials performed with the DES chose durations of
antiplatelet therapy based largely on preclinical experience
coupled with knowledge of the local drug release kinetics.
These trials, largely performed in low-risk patients based on
clinical and angiographic criteria, suggested that this strat-
egy was reasonable (7,8); thus, dual antiplatelet therapy for
3 months (sirolimus) and 6 months (paclitaxel) became
standard therapy after DES implantation (2,9,10). Data
from the CREDO (Clopidogrel for Reduction of Events
During Observation) (11) and CURE (Clopidogrel in
Unstable Angina to Prevent Recurrent Events) trials (12)
supported more prolonged therapy up to 1 year with the
combination of aspirin and clopidogrel, especially among
specific groups of patients, including those with a recent
acute coronary syndrome.
Several months after the introduction of the sirolimus-
eluting stents into U.S. clinical practice, the Food and Drug
Administration issued a warning to physicians regarding the
risk of these new stents and subsequent thrombosis (13).
During the last few years questions have been raised about
the thrombotic risks that may be associated with delayed
endothelization of the DES (14), and the sponsors and
clinical investigators in the field provided reassurances based
on the low absolute risk of these events (15). The latest
perspective on this evolving controversy with the highest
level of clinical evidence to date is put forward by Pfisterer
et al. (16) in this issue of the Journal.
The BASKET-LATE (BAsel Stent Kosten-Effekivitäts
Trial-LAte Thrombotic Events) Investigators present the
long-term follow-up of a cohort of patients from the
BASKET trial (17), a study of a randomized comparison of
BMS with DES among a broad spectrum of unselected
patients from a single practice. In the BASKET trial, all
patients received the combination of aspirin plus clopidogrel
for 6 months; after the cessation of clopidogrel, the inves-
tigators prospectively followed patients who had had sur-
vived the first 6 months without an ischemic event. Between
7 and 18 months, they observed an increase in the death/
myocardial infarction composite among the DES patients
compared with the BMS patients (adjusted hazard ratio 2.2,
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p  0.03). The investigators had limited angiographic data
to document these clinical events as definite late thrombo-
ses, but the data available are consistent with the overall
observation. Their conclusion is carefully worded to note
that there was an observed continued lesser incidence of
target vessel revascularization with the DES and that the
late clinical events may only “possibly” be related to late
stent thrombosis.
Comments are warranted on the clinical dilemma leading
to this report, the study methodology and conduct, and the
limitations of the data and its interpretation. The incorpo-
ration of DES technology into clinical practice occurred
over approximately 18 months and has resulted in the use of
this technology in at least 80% of all U.S. PCI procedures
(18,19). As is frequently seen with new cardiac devices, a
rapid increase in clinical adoption quickly outstripped what
is known about the device from limited clinical trials.
Although BASKET-LATE was a single-center study from
a hub-and-spoke hospital system, the investigators should
be congratulated for efficiently using a previously random-
ized study cohort for this long-term observational study that
preserves some, but not all, of the internal validity of a
randomized comparison. Because most of the effort and
resources go into the organization and conduct of the
original trial, adding a second question and extending
follow-up is logistically efficient and scientifically helpful.
These investigators also demonstrate great commitment
to the research process, giving their study broader applica-
bility than might be typically ascribed to a single center
study, as they enrolled 84% of 988 consecutive patients
during a 13-month period. This complete integration of
clinical research and clinical practice deserves recognition
and praise. It also makes the results applicable to the broader
world of clinical practice as demonstrated by the large
percentage of patients with high-risk clinical characteristics
(including acute coronary syndromes) as well as challenging
anatomic subsets (chronic total occlusions, bifurcations, and
vein graft disease). The rate of follow-up was very high, and
the suspected clinical events were adjudicated by a commit-
tee blinded to the type of stent. The investigators also quite
cautiously and conservatively offer up their observations,
taking care to point out that the events were infrequent, that
their sample size was small, and that they had limited
angiographic data to confirm the events as definite stent
thrombosis, which is noteworthy as important discussions
can be sidetracked and further investigation delayed by
emotional displays on both sides of the argument (20).
It deserves mention, congratulations, and some discussion
that the authors received no industry sponsorship for this
study. The medical products industry provides most of the
financial support for clinical research involving drugs and
devices (21,22) in the U.S. This is neither surprising nor
intrinsically bad or improper. Our own research group at the
Duke Clinical Research Institute receives the majority of its
funding from industry sources. Little funding from public
sources is devoted to the study of drugs, devices, or
technology despite the fact that the public health as well as
criteria for use and reimbursement are completely depen-
dent on having an adequate knowledge base. During the last
20 years, there has been much productive collaboration be-
tween academic investigators and industry sponsors. Collabo-
rative investigation into fibrinolysis, statins, angiotensin-
converting enzyme inhibitors, beta-blockers, antithrombotic
therapies, and implantable defibrillators has resulted in knowl-
edge about drugs and devices that has dramatically improved
the plight of patients with cardiovascular disease.
However, the BASKET-LATE findings point to poten-
tially troubling changes in the clinical research world.
Although the possible risk of DES thrombosis was identi-
fied in preclinical studies and unproven signals have been
seen in clinical data, studies funded by the stent industry
have been slow to follow-up. It took an independent study
funded by the Swiss government and a registry funded by a
pharmaceutical firm (23) to raise this signal to a high level
of consciousness. Research focusing on regulatory approval
focuses on the appropriate need of companies that market
medical products to optimize individual products as finan-
cial assets. Although this system obviously advances better
public health through appropriate product approval and
labeling, it does not necessarily have the imperative either to
fine-tune the posing of research questions to maximize the
impact on clinical care or to improve the public health.
Important questions that might lead to less use of a product
often lack sufficient funding to be pursued, and comparative
trials of commonly used therapeutic strategies infrequently
are performed, particularly when the alternative is generic
and not driven by marketing concerns. One disconcerting
feature of this issue is the continued growth of research as a
business that is disconnected from the continuum of knowl-
edge needed to inform patients and their doctors about
therapeutic options. Some members of the commercial
contract research industry have identified academic health
centers as the competition rather than collaborators in a
mutual effort to improve the knowledge base for improved
health outcomes (24); the commercial contract research
industry, as with any profit-making entity, seeks mainly and
legitimately to pursue that profit without the ethical imper-
ative to improve either the research process or the public
health. Clinical practitioners and academic leaders need to
push for collaboration with industry that is mutually re-
spectful of each other’s goals while maintaining a critical
degree of independence, especially regarding data manage-
ment and analysis and result interpretation. To do otherwise
is to abdicate our contract with society.
What might the results from BASKET-LATE mean for
our patients and for the continued development of DES
technology? Given the unprecedented uptake of DES into
cardiovascular care, are we committing millions of patients
to lifelong potent antithrombotic therapy with its attendant
costs and risks, especially regarding bleeding or ischemia
after interruption? Spertus et al. (23) recently reported that,
among a group of patients receiving DES after acute
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myocardial infarction, 13.6% had discontinued clopidogrel
by 30 days after hospitalization and had a highly significant
increased risk of death during the next 11 months (adjusted
hazard ratio 9.0, 95% confidence interval 1.3 to 60.6). These
findings, coupled with BASKET-LATE, have led us to the
view that patients with DES should remain on clopidogrel
and aspirin if at all possible until adequate studies are
completed that, first, fully depict the trade-off of the benefit
of DES with the risk of late thrombosis and, second, lead us
to understand the time-oriented risk of stopping thienopy-
ridine treatment over a course of years rather than months.
Wise clinicians also should carefully consider the likelihood
that a patient will be able to adhere to a long-term
thienopyridine regimen and should consider a BMS strategy
when the risk of discontinuation exceeds the potential
benefit of the well-proven prevention of restensois with
DES. Understanding barriers to access to medications and
strategies to improve adherence are desperately needed (25).
Given the infrequent occurrence of many late events, it is
difficult, as with BASKET-LATE, to enroll enough pa-
tients in studies to place a high degree of certainty around an
observation. Investigators with access to relevant databases,
including academics, industry colleagues, and regulatory
authorities, should figure out efficient ways to collaborate
and share data and observations. This information should be
rapidly published and disseminated and should serve as
hypotheses for more prospective studies. Analyses need to
consider how best to balance the competing issues of
inhibiting neointimal proliferation and reducing endothelial
healing. Some appropriate answers might use techniques of
decision analysis that incorporate knowledge of patient
values and choices while other answers will come from
further consideration of the technology itself. Local drug
delivery is intuitively appealing, and perhaps the next
generation of polymers, stent materials, including bioab-
sorbable materials, and drugs may help address some of
these risks.
Equally important is a call to improve the research
process so that questions vital to society’s health can be
quickly prioritized and answered by a better integrated
system of clinical care and clinical research. Regarding the
specific clinical question of late ischemic events, under-
standing the relationships among choice of stenting, risk of
restenosis, adherence to antithrombotic therapies, and risk
of late cardiac events is critical. Clearly the best way to
answer this question would be through a randomized
clinical trial. Naysayers point out that a trial focusing on
late, infrequent events would be prohibitively large and
impossible to perform. The opposing perspective is that
hundred of thousands of procedures are performed annually
in the U.S. alone, making it quite possible to perform such
a definitive trial quickly given dedicated resources and
interest.
However, there are many other unanswered questions
being asked every day by concerned clinicians who are
limited in their ability to have them enter the national
discussion or to see them quickly answered. That should
worry all of us enough to be inspired to develop a more
effective and responsive clinical research system.
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